← WEST PHARMACEUTICAL SERVICES INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.5b |
$1.6b
+5.96%
|
$1.7b
+7.40%
|
$1.8b
+7.13%
|
$2.1b
+16.69%
|
$2.8b
+31.89%
|
$2.9b
+1.95%
|
$2.9b
+2.18%
|
$2.9b
-1.92%
|
$3.1b
+6.25%
|
$3.3b
+8.22%
|
|
| Cost of Revenue | $1.0b |
$1.1b
+7.79%
|
$1.2b
+7.87%
|
$1.2b
+5.31%
|
$1.4b
+11.74%
|
$1.7b
+20.06%
|
$1.8b
+5.73%
|
$1.8b
+3.99%
|
$1.9b
+4.07%
|
$2.0b
+3.98%
|
$2.1b
+6.75%
|
|
| Gross Profit | $501.1m |
$512.6m
+2.29%
|
$545.4m
+6.40%
|
$605.7m
+11.06%
|
$767.8m
+26.76%
|
$1.2b
+53.14%
|
$1.1b
-3.37%
|
$1.1b
-0.62%
|
$998.5m
-11.57%
|
$1.1b
+10.57%
|
$1.2b
+10.85%
|
|
| Research and Development Expense | $36.8m | $39.1m | $40.3m | $38.9m | $46.9m | $52.8m | $58.5m | $68.4m | $69.1m | $74.3m | $74.4m | |
| Selling, General and Administrative Expense | $239.8m | $242.6m | $262.9m | $272.7m | $302.0m | $362.8m | $316.9m | $353.4m | $338.5m | $393.6m | $426.8m | |
| Amortization of Intangible Assets | $2.6m | $2.4m | $2.7m | $3.4m | $4.4m | $5.4m | $3.7m | $3.6m | $3.6m | $2.8m | — | |
| Restructuring and Related Cost, Incurred Cost | $26.4m | $0 | $9.1m | $4.9m | $4.6m | $2.2m | $23.8m | ($2.8m) | ($2.5m) | $24.6m | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | $196.8m |
$228.9m
+16.31%
|
$240.3m
+4.98%
|
$296.6m
+23.43%
|
$406.9m
+37.19%
|
$752.3m
+84.89%
|
$734.0m
-2.43%
|
$676.0m
-7.90%
|
$569.9m
-15.70%
|
$584.9m
+2.63%
|
$722.6m
+23.54%
|
|
| Other Operating Income (Expense), Net | $100k | ($3.9m) | $4.8m | $4.9m | ($900k) | ($900k) | $600k | $0 | ($900k) | ($1.3m) | — | |
| Interest Expense, Debt | $11.7m | $10.5m | $9.3m | $9.4m | $9.6m | $10.2m | $11.6m | $14.8m | $16.2m | $15.1m | $4.5m | |
| Investment Income, Net | $1.1m | $1.3m | $2.1m | $3.8m | $1.4m | $1.0m | $5.1m | $28.0m | $19.6m | $17.5m | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | $0 | — | $1.5m | $1.4m | $4.1m | ($9.4m) | ($10.2m) | ($8.4m) | — | |
| Gain (Loss) on Investments | — | — | — | — | — | ($4.3m) | ($3.5m) | ($4.3m) | — | — | — | |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement | $0 | $0 | — | — | — | — | $52.2m | — | — | — | — | |
| Other Nonoperating Income (Expense) | $1.6m | $3.1m | $6.7m | ($100k) | $1.2m | $3.8m | ($51.3m) | $3.0m | ($1.0m) | ($1.0m) | — | |
| Interest Expense (non-operating) | $8.1m | $7.8m | $8.4m | $8.5m | $8.2m | $8.2m | $7.9m | $9.0m | $3.0m | $500k | $4.5m | |
| Income (Loss) from Equity Method Investments | $8.2m | $9.2m | $7.6m | $8.9m | $17.4m | $20.1m | $20.7m | $17.7m | $14.7m | $14.4m | — | |
| Interest Income (Expense), Nonoperating, Net | ($7.0m) | ($6.5m) | $6.7m | $100k | $1.2m | $3.8m | $51.3m | $3.0m | $1.0m | $1.0m | $18.7m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $84.5m | $96.5m | $132.9m | $161.2m | $227.0m | $420.0m | $394.4m | $369.4m | $243.4m | $228.3m | $693.6m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | — | — | — | $585.5m | $600.9m | $693.6m | |
| Current Income Tax Expense (Benefit) | $32.9m | $39.2m | $40.5m | $43.7m | $78.3m | $150.1m | $145.5m | $84.8m | $111.0m | $135.3m | $144.2m | |
| Income Tax Expense (Benefit) | $54.4m | $80.9m | $41.4m | $59.0m | $72.5m | $107.2m | $114.7m | $122.3m | $107.5m | $121.6m | $144.2m | |
| Net Income (Loss) Attributable to Parent | $143.6m |
$150.7m
+4.94%
|
$206.9m
+37.29%
|
$241.7m
+16.82%
|
$346.2m
+43.24%
|
$661.8m
+91.16%
|
$585.9m
-11.47%
|
$593.4m
+1.28%
|
$492.7m
-16.97%
|
$493.7m
+0.20%
|
$564.9m
+14.42%
|
|
| Earnings Per Share, Basic | $1.96 | $2.04 | $2.80 | $3.27 | $4.68 | $8.89 | $7.87 | $7.98 | $6.75 | $6.83 | $7.87 | |
| Earnings Per Share, Diluted | $1.91 | $1.99 | $2.74 | $3.21 | $4.57 | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 | $7.81 | |
| Common Stock, Dividends, Per Share, Declared | $0.50 | $0.54 | $0.58 | $0.62 | $0.66 | $0.70 | $0.74 | $0.78 | $0.82 | $0.86 | — | |
| Weighted Average Number of Shares Outstanding, Basic | 73.3m | 73.9m | 73.9m | 74.0m | 73.9m | 74.4m | 74.4m | 74.3m | 73.0m | 72.3m | 71.8m | |
| Weighted Average Number of Shares Outstanding, Diluted | 75.0m | 75.8m | 75.4m | 75.4m | 75.8m | 76.3m | 75.8m | 75.3m | 73.7m | 72.7m | 72.2m | |
| Additional Financial Items | ||||||||||||
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | — | — | — | — | $300k | $4.5m | — | |
| Goodwill, Impairment Loss | — | — | — | — | — | $100k | — | — | — | — | $3.7m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.